Rimonabant (Acomplia®), specific inhibitor of the endocannabinoid system;Le rimonabant (Acomplia®), inhibiteur spécifique du système endocannabinoïde

Revue Medicale de Bruxelles

Volumn 26, Issue 3, 2005, Pages 165-168

  Ducobu, J ^a   Sternon, J ^b  

^a Centre Hospitalier Universitaire de Tivoli   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Dyslipidemia; Obesity; Rimonabant; Tobacco addiction

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; CANNABINOID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADIPOCYTE; APPETITE; ARTICLE; BODY FAT; DRUG TOLERABILITY; DYSLIPIDEMIA; ENERGY; FOOD INTAKE; HUMAN; HYPOTHALAMUS; LOW CALORY DIET; NONHUMAN; OBESITY; REGULATORY MECHANISM; SIDE EFFECT; TOBACCO DEPENDENCE; WAIST CIRCUMFERENCE; ANIMAL; DRUG ANTAGONISM;

ANIMALS; CANNABINOIDS; HUMANS; PIPERIDINES; PYRAZOLES;

EID: 21744437794     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Cota D, Marsicano G, Tschop M et al: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31
2. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84
3. Cota D, Genghini S, Pasquali R, Pagotto U: Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity. J Endocrinol Invest 2003; 26: 1041-4
4. Ducobu J: Le système endocannabinoïde et la régulation du métabolisme. Rev Med Brux 2005; 26: 159-64
5. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P: SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002; 13: 451-63
6. Ravinet Trillou C, Arnone M, Delgorge C et al: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-53
7. Yamauchi T, Kamon J, Waki H et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6
8. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: RIO-EUROPE Study Group: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-EUROPE study. Lancet 2005; 365: 1389-97
9. Pagotto U, Pasquali R: Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptor. Lancet 2005; 365: 1363-4